Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Researcher shares platform with Nobel Laureate at conference on nanomedicine
2013-01-10

Prof. Lodewyk Kock at the Everest viewpoint with Mount Everest behind him.
10 January 2013

Profs. Lodewyk Kock and Robert Bragg from the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS) both presented lectures at the first International Conference on Infectious Diseases and Nanomedicine that was held in Kathmandu, Nepal, late last year.

At the conference, also attended by senior representatives from the International Union of Microbiological Societies (IUMS), Prof. Kock delivered one of the two opening lectures, titled: Introducing New Nanotechnologies to Infectious Diseases (the other opening lecture was presented by Nobel Laureate, Prof. Barry J. Marshal). Prof. Kock also participated in the farewell address.

In two excellent lectures, Prof. Bragg spoke on Bacteriophages as potential treatment option of antibiotic-resistant bacteria, and on Bacterial resistance to quaternary ammonium compounds.

For Prof. Kock this very first conference on infectious diseases and nanomedicine was followed by a very exciting yeast research excursion through the Mount Everest Highway which winds through the villages of the Sherpa tribe.

He describes his journey: “The Mount Everest Highway is a rough road stretching through hills and glacial moraines of unfamiliar altitudes and cold temperatures. Throughout the journey I had to take care of not contracting altitude sickness which causes severe headaches and dizziness.

“The only way of transport is on foot, on long-haired cattle called Yaks, donkeys and by helicopter. After flying by plane from Kathmandu (the capital of Nepal), I landed at Lukla, regarded as the most dangerous airport in the world due to its short elevated runway and mountainous surroundings. From Lukla, the land of the Sherpa, I walked (trekked) with my Sherpa guide and porter (carrier) along the Everest Highway surrounded by various Buddhist Mani scripture stands, other Buddhist representations and many spectacular snow-tipped mountains of more than 6 000 m above sea level. Of these, the majestic mountain called Ama Dablam (6 812 m), the grand 8 516 m high peak of Lhotse and to its left the renowned Mount Everest at 8 848 m in height, caught my attention.

“Dwarfed by these mountain peaks on the horizon, I passed various villages until I eventually reached the beautiful village called Namche Bazar, the heart of the Khumbu region and hometown of the Sherpa. This took three days of up to six hours walking per day, while I spent the nights at the villages of Phakding and Monjo. From there I walked along the Dudh Kosi River which stretches towards Mount Everest, until I reached the high altitude Everest viewpoint – the end of my journey, after which I trekked back to Lukla to return to Kathmandu and South Africa.

“This expedition is the first exploration to determine the presence of yeasts in the Everest region. Results from this excursion will be used in collaborative projects with local universities in Nepal that are interested in yeast research.”

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept